Yili Pharma raises nearly RMB 400m Series A for radiopharma
Huagai Capital leads a sizable A round for a China radiopharma company pushing candidates toward the clinic.
What moved. Yili Pharma (亦立医药) said it closed a Series A of nearly RMB 400 million, led by Huagai Capital with Kangjun Capital as co-lead, and a long list of new and existing backers including CSPC-linked capital among continuing shareholders, according to the company’s financing announcement as carried in Chinese industry briefings on 12 Nov 2026.
The number. Proceeds are earmarked for preclinical work, IND enabling, early clinical development, platform build-out, and international expansion for a radiopharma pipeline aimed at oncology and neurological disease “theranostics.”
Why it matters. Radiopharma remains a crowded China financing theme. For capital and BD desks, the signal is less the headline raise than whether the next disclosures name targets, IND timelines, and partnering intent—especially as more China radiopharma stories compete for the same overseas partner attention.
Industry information only—not medical or investment advice.
